LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
医学
无容量
内科学
肿瘤科
癌症
免疫疗法
作者
N. Girard,Mauricio Burotto,L.G. Paz-Ares,Martin Reck,M. Schenker,A. Lingua,F.J. Orlandi,J. Naidoo,E.K. Beardlsey,Vamsidhar Velcheti,G.L. Martinengo,E. Felip,Y. Zhang,P. Kasbekar,Munir Chowdhury,Thomas E. Spires,Amol Tendolkar,Manuel Cobo
出处
期刊:Annals of Oncology [Elsevier BV] 日期:2024-09-01卷期号:35: S1243-S1244被引量:3